Video content material above is prompted by the next questions:
- Focus on the information that was offered on the 2024 ASCO Annual Assembly on the progression-free survival from the section 3 trial LAURA of osimertinib in sufferers with unresectable stage III EGFR-mutated NSCLC with out development after definitive CRT.
- What are your key takeaways from this research and the way will it impression the present commonplace of look after EGFR-mutated NSCLC?
